GO:0010544 negative regulation of platelet activation: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010544 (negative regulation of platelet activation) describes any process that decreases the rate or frequency of platelet activation, a series of progressive, overlapping events triggered by exposure of platelets to subendothelial tissue.
• Negative regulators of platelet activation are essential for preventing excessive thrombosis while preserving hemostasis, and their dysfunction contributes to cardiovascular disease.
• Key negative regulators include NR4A1, TULA-family proteins, diacylglycerol kinase zeta, pyruvate kinase M2, and IL-37, which act through diverse signaling pathways.
• These regulators modulate platelet activation by interfering with GPVI-mediated signaling, tyrosine phosphatase activity, metabolic reprogramming, and inflammatory cytokine pathways.
• Dysregulation of negative regulators is linked to thrombosis, atherosclerosis, and inflammatory diseases, making them attractive therapeutic targets.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of these regulatory mechanisms in platelets.
Description
Platelets are anucleate blood cells that play a central role in hemostasis and thrombosis. Upon exposure to subendothelial tissue, platelets undergo a series of progressive, overlapping events collectively termed platelet activation, which includes shape change, granule secretion, and aggregation. While positive regulators of platelet activation are well characterized, negative regulators that dampen these responses are equally important for preventing pathological thrombosis. GO:0010544, negative regulation of platelet activation, encompasses any process that decreases the rate or frequency of platelet activation. Understanding these negative regulatory mechanisms is critical for developing targeted antithrombotic therapies that do not impair hemostasis. Recent studies have identified several negative regulators, including NR4A1, TULA-family proteins, diacylglycerol kinase zeta, pyruvate kinase M2, and IL-37, which act through distinct molecular pathways to restrain platelet activation. These discoveries have been facilitated by advances in genetic and pharmacological tools, including CRISPR-based gene editing, which allow precise manipulation of candidate genes in platelet models. This article provides a comprehensive overview of GO:0010544, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and research methodologies.
negative regulation of platelet activation At A Glance
| GO ID | GO:0010544 |
|---|---|
| GO term | negative regulation of platelet activation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate or frequency of platelet activation, thereby preventing excessive thrombosis while preserving hemostasis |
| Definition source | QuickGO definition: Any process that decreases the rate or frequency of platelet activation. Platelet activation is a series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. |
| Related processes | Platelet activation, platelet aggregation, hemostasis, thrombosis |
| Key negative regulators | NR4A1, TULA-family proteins, diacylglycerol kinase zeta, pyruvate kinase M2, IL-37 |
| Disease relevance | Thrombosis, cardiovascular disease, inflammatory diseases |
What Is GO:0010544?
GO:0010544, negative regulation of platelet activation, is a biological process defined as any process that decreases the rate or frequency of platelet activation. Platelet activation itself is a series of progressive, overlapping events triggered by exposure of platelets to subendothelial tissue. This negative regulation can occur through various molecular mechanisms, including inhibition of signaling pathways downstream of platelet receptors, modulation of metabolic enzymes, and regulation of inflammatory mediators. The term is distinct from positive regulation of platelet activation and is essential for maintaining vascular homeostasis by preventing excessive platelet aggregation and thrombosis.
Why Is negative regulation of platelet activation Important in Cell Biology?
Negative regulation of platelet activation is crucial for maintaining the delicate balance between hemostasis and thrombosis. While platelet activation is necessary to stop bleeding, uncontrolled activation can lead to pathological thrombus formation, which underlies myocardial infarction, ischemic stroke, and venous thromboembolism. Negative regulators act as brakes on platelet activation, preventing excessive aggregation at sites of minor injury and limiting thrombus growth. Dysregulation of these negative regulators has been implicated in various diseases, including cardiovascular disorders and inflammatory conditions. Moreover, understanding these mechanisms can inform the development of safer antithrombotic therapies that target negative regulators without causing bleeding complications. Recent research has identified novel negative regulators such as NR4A1, TULA-family proteins, and IL-37, highlighting the complexity and therapeutic potential of this process.
• Prevents excessive platelet activation and thrombosis while preserving normal hemostasis.
• Dysregulation contributes to cardiovascular diseases such as myocardial infarction and stroke.
• Negative regulators are potential therapeutic targets for antithrombotic therapy with reduced bleeding risk.
• NR4A1 acts as a novel regulator of platelet activation and thrombus formation, offering a new target.
• TULA-family proteins provide a paradigm for negative regulation through ubiquitin-associated domains.
• Diacylglycerol kinase zeta specifically dampens GPVI-mediated platelet activation.
• Pyruvate kinase M2 links metabolic reprogramming to platelet function and arterial thrombosis.
• IL-37 attenuates platelet activation and thrombosis through the IL-1R8 pathway, linking inflammation to thrombosis.
• Understanding negative regulation aids in identifying biomarkers for thrombotic risk.
• CRISPR-based models enable precise functional studies of negative regulators in platelets.
What Happens During negative regulation of platelet activation?
Initiation of negative regulatory signaling
In simple terms: The process begins when molecules that put the brakes on platelet activation are triggered.
Negative regulation of platelet activation is initiated by various extracellular and intracellular cues that activate inhibitory receptors or pathways. For example, IL-37 binds to IL-1R8 on platelets, initiating a signaling cascade that dampens platelet activation. Similarly, NR4A1, a nuclear receptor, is rapidly induced upon platelet activation and acts as a negative feedback regulator. TULA-family proteins, which contain ubiquitin-associated domains, are recruited to activated receptors and downregulate signaling. These initiation events are critical for setting the threshold for platelet responsiveness.
Inhibition of GPVI-mediated signaling
In simple terms: One major way platelets are restrained is by blocking the signals that come from collagen receptors.
Diacylglycerol kinase zeta (DGKζ) is a key negative regulator of GPVI-mediated platelet activation. Upon GPVI stimulation, DGKζ metabolizes diacylglycerol to phosphatidic acid, thereby limiting the activation of protein kinase C and downstream signaling events. This mechanism specifically attenuates collagen-induced platelet activation without affecting other pathways, highlighting the specificity of negative regulation. Similarly, TULA-family proteins can deubiquitinate or modulate signaling molecules downstream of GPVI, further contributing to inhibition.
Metabolic control of platelet activation
In simple terms: Platelet activation requires energy, and certain metabolic enzymes can put a brake on this process.
Pyruvate kinase M2 (PKM2) is a metabolic enzyme that regulates platelet function and arterial thrombosis. PKM2 deficiency or inhibition leads to enhanced platelet activation, indicating that PKM2 acts as a negative regulator. PKM2 modulates platelet metabolism and redox balance, and its loss results in increased mitochondrial respiration and reactive oxygen species production, which promote platelet activation. This links metabolic reprogramming to the negative regulation of platelet activation.
Regulation by phosphatases and kinases
In simple terms: Enzymes that add or remove phosphate groups can turn down platelet activation.
Protein tyrosine phosphatase 1B (PTP1B) is activated by platelet-activating factor (PAF) through a Janus kinase 2 (JAK2)/calpain pathway, and it negatively regulates platelet activation by dephosphorylating key signaling proteins. Additionally, NR4A1 has been shown to inhibit platelet activation by modulating the expression of target genes and interfering with signaling pathways. These phosphatase and kinase networks provide additional layers of negative regulation.
Inflammatory pathways as negative regulators
In simple terms: Some anti-inflammatory molecules also help to calm platelets down.
IL-37, an anti-inflammatory cytokine, attenuates platelet activation and thrombosis through the IL-1R8 pathway. IL-37 binding to IL-1R8 on platelets inhibits agonist-induced platelet aggregation, granule secretion, and integrin αIIbβ3 activation. This demonstrates that inflammatory mediators can directly suppress platelet activation, linking inflammation resolution to thrombus prevention.
Mitochondrial transfer and extracellular vesicles
In simple terms: Platelets can transfer mitochondria to other cells, which may influence their own activation state.
Platelet mitochondrial transfer via extracellular vesicles modulates neutrophil phenotype and function, and this process may also impact platelet activation. Although the direct role in negative regulation of platelet activation is not fully elucidated, extracellular vesicles derived from platelets can carry regulatory molecules that affect platelet function. This emerging area highlights the complexity of negative regulation in the vascular microenvironment.
Key Genes Involved in GO:0010544 negative regulation of platelet activation
The following genes and proteins have been experimentally implicated in the negative regulation of platelet activation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR4A1 | Nuclear receptor that acts as a negative feedback regulator of platelet activation and thrombus formation | Novel target for antithrombotic therapy; studied via knockout and overexpression models |
| TULA-family (e.g., TULA-2) | Protein tyrosine phosphatases that downregulate platelet activation through ubiquitin-associated domains | Paradigm for negative regulation; potential targets for modulating platelet reactivity |
| DGKZ (DGKζ) | Diacylglycerol kinase that metabolizes DAG to limit GPVI-mediated platelet activation | Specific regulator of collagen-induced activation; knockout models show enhanced platelet responses |
| PKM2 | Pyruvate kinase M2 that regulates platelet metabolism and negatively controls platelet activation and arterial thrombosis | Links metabolism to platelet function; potential target for metabolic modulation |
| IL37 | Anti-inflammatory cytokine that attenuates platelet activation via IL-1R8 | Connects inflammation to thrombosis; therapeutic potential in inflammatory thrombosis |
| PTPN1 (PTP1B) | Protein tyrosine phosphatase activated by PAF via JAK2/calpain, negatively regulates platelet activation | Regulator of tyrosine phosphorylation; studied in PAF-mediated activation |
| JAK2 | Kinase involved in PAF-mediated PTP1B activation, contributing to negative regulation | Part of signaling cascade that dampens platelet activation |
| CAPN1 (Calpain) | Protease that activates PTP1B in response to PAF, mediating negative regulation | Potential modulator of platelet signaling |
| IL1R8 | Receptor for IL-37 that mediates inhibitory signaling in platelets | Target for anti-inflammatory antithrombotic strategies |
| GP6 (GPVI) | Collagen receptor whose signaling is negatively regulated by DGKζ and TULA-family proteins | Central to platelet activation; negative regulators act downstream |
| ITGA2B (αIIb) | Integrin subunit whose activation is inhibited by negative regulators like IL-37 | Marker of platelet activation; target of negative regulation |
| ITGB3 (β3) | Integrin subunit forming αIIbβ3, inhibited by negative regulators | Key effector of aggregation; modulated by negative pathways |
| SELP (P-selectin) | Adhesion molecule whose surface exposure is reduced by negative regulators | Marker of granule secretion; used to assess negative regulation |
| VWF | Von Willebrand factor that mediates platelet adhesion; negative regulators may modulate its effects | Relevant to thrombus formation under flow |
| F2 (Thrombin) | Coagulation factor that activates platelets; negative regulators can counteract thrombin signaling | Target of negative feedback in thrombosis |
| PDGFB | Platelet-derived growth factor stored in granules; its release is reduced by negative regulators | Marker of granule secretion; reflects platelet activation status |
| PF4 (CXCL4) | Platelet factor 4 released upon activation; negative regulators reduce its secretion | Chemokine involved in thrombosis and inflammation |
| THBS1 | Thrombospondin-1 released from alpha granules; negative regulators limit its release | Adhesive protein modulating platelet-platelet interactions |
How Is negative regulation of platelet activation Regulated?
The negative regulation of platelet activation is itself tightly regulated at multiple levels. Transcriptional regulation, such as induction of NR4A1 upon platelet activation, provides a feedback mechanism. Post-translational modifications, including phosphorylation and ubiquitination, control the activity of negative regulators like TULA-family proteins and PTP1B. Metabolic cues, such as those sensed by PKM2, link platelet function to cellular energy status. Inflammatory mediators like IL-37 can upregulate inhibitory pathways through IL-1R8. Additionally, extracellular vesicles and mitochondrial transfer may modulate the local environment to influence platelet reactivity. These regulatory layers ensure that platelet activation is balanced and responsive to physiological needs.
negative regulation of platelet activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NR4A1 | Thrombosis, cardiovascular disease | Knockout and overexpression in platelet-specific models |
| IL37 | Inflammatory thrombosis, cardiovascular disease | Knock-in and knockout mouse models; IL-1R8 pathway |
| PKM2 | Arterial thrombosis, metabolic disorders | Platelet-specific knockout and pharmacological inhibition |
| DGKZ | GPVI-mediated thrombosis, collagen-induced activation | Knockout mice and point mutation models |
| TULA-2 | Platelet reactivity, immune-mediated thrombosis | Knockout and phosphatase-dead knock-in models |
Thrombosis and Cardiovascular Disease
Dysregulation of negative regulators of platelet activation contributes to pathological thrombosis. For example, NR4A1 deficiency enhances platelet activation and thrombus formation in vivo, suggesting that loss of this negative regulator predisposes to thrombosis. Similarly, IL-37 attenuates platelet activation and thrombosis, and its downregulation may exacerbate thrombotic risk. PKM2 deficiency leads to enhanced platelet activation and arterial thrombosis, indicating that metabolic negative regulators are critical for vascular homeostasis. These findings highlight the therapeutic potential of targeting negative regulators to prevent cardiovascular events.
Inflammatory and Immune Disorders
Negative regulators of platelet activation also play roles in inflammatory diseases. IL-37, an anti-inflammatory cytokine, suppresses platelet activation through IL-1R8, linking inflammation resolution to thrombosis prevention. PTP1B, activated by PAF via JAK2/calpain, may modulate platelet responses in inflammatory settings. TULA-family proteins, which are expressed in hematopoietic cells, may influence platelet function in immune-mediated disorders. Thus, negative regulation of platelet activation is intertwined with inflammatory pathways, and its dysregulation may contribute to diseases such as atherosclerosis and sepsis.
Bleeding Disorders and Hemostasis
While excessive negative regulation could theoretically lead to bleeding, current evidence suggests that these pathways are finely tuned to prevent thrombosis without impairing hemostasis. For instance, DGKζ deficiency enhances GPVI-mediated platelet activation but does not cause spontaneous bleeding in mice. This suggests that targeting specific negative regulators may provide a safe antithrombotic strategy. However, further research is needed to fully understand the impact of modulating these pathways on hemostasis.
From negative regulation of platelet activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NR4A1 enhance platelet activation and thrombosis? | Platelet-specific NR4A1 knockout mouse |
| Does IL-37 inhibit platelet activation via IL-1R8? | IL-37 overexpression or IL-1R8 knockout models |
| Does PKM2 deficiency alter platelet metabolism and thrombosis? | PKM2 knockout or point mutation models |
| Does DGKζ specifically regulate GPVI signaling? | DGKζ knockout and point mutation (kinase-dead) models |
| Does TULA-2 phosphatase activity regulate platelet activation? | TULA-2 knockout and phosphatase-dead knock-in |
| Does PTP1B activation by PAF require JAK2/calpain? | JAK2 or calpain knockout; PTP1B point mutants |
How to Study the negative regulation of platelet activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Light transmission aggregometry | Platelet aggregation in response to agonists | Assessing negative regulators in knockout/transgenic platelets |
| Flow cytometry | Surface markers of activation (P-selectin, PAC-1) | Quantifying platelet activation state |
| Intravital microscopy | Real-time thrombus formation in vivo | Evaluating thrombosis in animal models |
| Western blotting | Protein phosphorylation and expression | Analyzing signaling pathways |
| Immunoprecipitation | Protein-protein interactions | Identifying complexes involving negative regulators |
| Lumi-aggregometry | ATP release (dense granule secretion) | Measuring secretion alongside aggregation |
| ELISA | Soluble markers (e.g., PF4, TXB2) | Quantifying granule release |
| CRISPR screening | Gene function at scale | Identifying novel negative regulators |
Platelet aggregation and secretion assays
Light transmission aggregometry and lumi-aggregometry are standard methods to assess platelet activation and the impact of negative regulators. These assays measure platelet aggregation in response to agonists such as collagen, thrombin, or ADP, and can be used with platelets from knockout or transgenic models. Dense and alpha granule secretion can be measured by ATP release or P-selectin surface exposure.
Flow cytometry for platelet activation markers
Flow cytometry is used to quantify platelet activation markers such as P-selectin (CD62P) exposure, integrin αIIbβ3 activation (PAC-1 binding), and phosphatidylserine exposure. This method is highly sensitive and can be applied to whole blood or washed platelets, enabling assessment of negative regulators in physiological contexts.
Intravital microscopy and thrombosis models
Intravital microscopy allows real-time visualization of platelet adhesion, aggregation, and thrombus formation in living animals. Models of arterial injury (e.g., FeCl3-induced or laser-induced) are used to evaluate the role of negative regulators in thrombosis in vivo. These techniques provide spatial and temporal insights into platelet dynamics.
Biochemical signaling assays
Western blotting, immunoprecipitation, and phospho-specific antibodies are used to analyze signaling pathways downstream of platelet receptors. For example, phosphorylation of PLCγ2, PKC substrates, or Akt can be assessed to determine how negative regulators modulate signaling. These methods help define molecular mechanisms.
How CRISPR Can Be Used to Study GO:0010544 negative regulation of platelet activation
Knockout
CRISPR-Cas9 knockout is widely used to delete candidate negative regulator genes in platelet models, such as megakaryocyte cell lines or primary hematopoietic stem cells. For example, NR4A1 knockout mice generated via CRISPR show enhanced platelet activation and thrombosis. Similarly, PKM2 knockout platelets exhibit increased activation, confirming its negative regulatory role. Knockout studies are essential for establishing causality.
Point Mutation
Point mutations can be introduced to dissect specific domains or catalytic activities. For instance, phosphatase-dead mutants of TULA-2 can be generated to test whether its phosphatase activity is required for negative regulation. Kinase-dead DGKζ mutants can clarify the importance of its catalytic activity in GPVI signaling. These models provide mechanistic insights beyond simple knockout.
Knock-in
Knock-in models allow expression of tagged or mutant proteins at endogenous loci. For example, a tagged NR4A1 knock-in can be used to study its interactome and localization in platelets. IL-37 knock-in mice can be used to assess its effect on thrombosis in vivo. Knock-in strategies are valuable for physiological expression studies.
Overexpression
Overexpression of negative regulators in platelet lineages can test whether increased levels suppress platelet activation. For example, IL-37 overexpression attenuates platelet activation and thrombosis. Overexpression of DGKζ reduces GPVI-mediated activation. These models are useful for gain-of-function studies and therapeutic target validation.
How EDITGENE Supports negative regulation of platelet activation Research
Researchers studying negative regulation of platelet activation-related genes often need to determine whether a candidate gene is causally involved in restraining platelet function. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress the gene of interest in relevant cell types. EDITGENE provides comprehensive CRISPR-based services to accelerate such studies, from single gene editing to high-throughput library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of platelet activation research.
Frequently Asked Questions About negative regulation of platelet activation
What is GO:0010544?
GO:0010544 is the Gene Ontology term for negative regulation of platelet activation, defined as any process that decreases the rate or frequency of platelet activation, which is a series of progressive, overlapping events triggered by exposure of platelets to subendothelial tissue.
What genes are involved in negative regulation of platelet activation?
Key genes include NR4A1, TULA-family proteins (e.g., TULA-2), DGKZ (DGKζ), PKM2, IL37, PTPN1 (PTP1B), JAK2, CAPN1, and IL1R8, among others.
How does NR4A1 regulate platelet activation?
NR4A1 acts as a negative feedback regulator; its induction upon platelet activation dampens further activation and thrombus formation, as shown in knockout models.
What is the role of TULA-family proteins in platelets?
TULA-family proteins are phosphatases that downregulate platelet activation through ubiquitin-associated domains, serving as negative regulators of signaling.
How does diacylglycerol kinase zeta inhibit platelet activation?
DGKζ metabolizes diacylglycerol to phosphatidic acid, thereby limiting protein kinase C activation and specifically attenuating GPVI-mediated platelet activation.
What is the link between PKM2 and platelet activation?
PKM2 is a metabolic enzyme that negatively regulates platelet activation; its deficiency leads to enhanced platelet activation and arterial thrombosis.
How does IL-37 affect platelets?
IL-37 attenuates platelet activation and thrombosis through the IL-1R8 pathway, inhibiting aggregation, secretion, and integrin activation.
What diseases are associated with dysregulated negative regulation of platelet activation?
Dysregulation is linked to thrombosis, cardiovascular disease, and inflammatory disorders, as negative regulators prevent excessive platelet activation.
What experimental models are used to study negative regulation of platelet activation?
Common models include knockout mice, point mutation knock-ins, overexpression systems, and CRISPR screens in megakaryocyte cell lines or primary cells.
How can CRISPR help study negative regulators of platelet activation?
CRISPR enables precise knockout, point mutation, knock-in, and overexpression of candidate genes, allowing causal testing of their roles in platelet activation and thrombosis.
Conclusion
GO:0010544, negative regulation of platelet activation, represents a critical counterbalance to prothrombotic signaling, ensuring that platelets respond appropriately to vascular injury without causing pathological thrombosis. The identification of diverse negative regulators such as NR4A1, TULA-family proteins, DGKζ, PKM2, and IL-37 has illuminated the complexity of these inhibitory pathways. Dysregulation of these mechanisms contributes to cardiovascular and inflammatory diseases, making them attractive therapeutic targets. Advances in CRISPR-based gene editing have accelerated functional studies, enabling precise manipulation of candidate genes in platelet models. Continued research into the negative regulation of platelet activation promises to yield safer antithrombotic strategies and deeper insights into hemostasis.
References
- 1. Liu W et al.. 2025. NR4A1 Acts as a Novel Regulator of Platelet Activation and Thrombus Formation.. Circ Res 136(8):809-826 PMID: 40035146
- 2. Stefanini L et al.. 2018. Negative regulators of platelet activation and adhesion.. J Thromb Haemost 16(2):220-230 PMID: 29193689
- 3. Kunapuli SP et al.. 2022. TULA-Family Regulators of Platelet Activation.. Int J Mol Sci 23(23) PMID: 36499237
- 4. Nayak MK et al.. 2021. The metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis.. Blood 137(12):1658-1668 PMID: 33027814
- 5. Allan HE et al.. 2025. Platelet mitochondrial transfer via extracellular vesicles modulates neutrophil phenotype and function.. J Thromb Haemost 23(11):3665-3677 PMID: 40846030
- 6. Moroi AJ et al.. 2019. Diacylglycerol kinase ζ is a negative regulator of GPVI-mediated platelet activation.. Blood Adv 3(7):1154-1166 PMID: 30967391
- 7. Hamel-Côté G et al.. 2017. Regulation of platelet-activating factor-mediated protein tyrosine phosphatase 1B activation by a Janus kinase 2/calpain pathway.. PLoS One 12(7):e0180336 PMID: 28686728
- 8. Chen Y et al.. 2023. IL-37 Attenuates Platelet Activation and Thrombosis Through IL-1R8 Pathway.. Circ Res 132(9):e134-e150 PMID: 36999436
